Lay summary
The curent Covid-19 infection pandemic is requiring prolonged ventilation support in many patients. We have a therapy (repurposed drug) expected to reduce lung injury in these clinical circumstances. This study will provide key initial experimental data for this indication to then support a decision to re-manufacture the drug and use it in a covid clinical trial.